Hycamtin
(Topotecan)ApprovedSmall molecule
Topotecan is used to treat certain types of cancer, including ovarian cancer, small cell lung cancer, and cervical cancer. It works by stopping cancer cells from dividing and growing.[2] Hycamtin is currently approved and in use across 60 indications[4].[1]
Hycamtin is one of 968 small molecule programs targeting Glioma. It is currently in Approved.
60
Indications
221
Total Trials
42
Active Trials
967
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 60 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Hycamtin
MMeitheal
Approved
Halaven
EisaiPreclinical
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer38 trials
Show 35 more trials
Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Unknown status·—·Phase 2·NCT04213937·386 enrolled
Ovarian Cancer28 trials
Show 25 more trials
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Terminated·—·Phase 1/2·NCT00526799·30 enrolled
Neuroblastoma12 trials
Show 9 more trials
High-Risk Neuroblastoma Chemotherapy Without G-CSF
Completed·—·N/A·NCT02786719·13 enrolled
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
Active, not recruiting·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT02298348·18 enrolled
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05303727·64 enrolled
Cervical Cancer9 trials
Show 6 more trials
Lung Cancer8 trials
Show 5 more trials
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
Unknown status·—·Phase 2·NCT02980809·60 enrolled
64 more indications
Fallopian Tube Cancer5 trials
Glioma4 trials
Retinoblastoma4 trials
A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
Terminated·—·Phase 2·NCT04455139·2 enrolled
Show 1 more trial
Chemotherapy4 trials
Cervical Carcinoma3 trials
Multiple Myeloma3 trials
Refractory Solid Tumors3 trials
Primary Peritoneal Cancer3 trials
Advanced Solid Tumors3 trials
Solid Tumors3 trials
Non-Small Cell Lung Cancer3 trials
Endometrial Cancer3 trials
Medulloblastoma2 trials
Lymphoma2 trials
Peritoneal Cancer2 trials
Primary Peritoneal Carcinoma2 trials
Patients With Advanced Solid Tumors2 trials
Acute Leukemia2 trials
Refractory2 trials
Advanced Malignancies2 trials
Malignancies2 trials
Relapsed or Refractory1 trial
Malignant Glioma1 trial
Chronic CED of TPT for Recurrent Malignant Glioma
Recruiting·—·Phase 1·NCT06666712·6 enrolled
Relapse1 trial
Clinical Trial1 trial
Chronic1 trial
Chronic Convection Enhanced Delivery of Topotecan
Completed·—·Phase 1·NCT03154996·5 enrolled
Liposomal Doxorubicin1 trial
Refractory or Recurrent Solid Tumor1 trial
Soft Tissue Sarcoma1 trial
Rhabdomyosarcoma1 trial
Acute Myeloid Leukemia1 trial
Newly Diagnosed1 trial
Rectal Carcinoma1 trial
Recurrent1 trial
Papilloma1 trial
Malignant Brain Tumors1 trial
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
Terminated·NNicklaus Children's Hospital f/k/a Miami Children's Hospital·Phase 2·NCT02684071·3 enrolled
Clear Cell Carcinoma1 trial
Ovarian Carcinoma1 trial
Induction Chemotherapy1 trial
Metastasis1 trial
Meningitis1 trial
Phase 1 Intrathecal Topotecan for Neoplastic Meningitis
Completed·—·Phase 1·NCT00674674·22 enrolled
Patients With Solid Tumors1 trial
Small Cell Cancer1 trial
Solid Neoplasms1 trial
COVID-191 trial
SCLC1 trial
Study in Patients With SCLC of Veliparib in Combination With Topotecan
Unknown status·CCentral European Society for Anticancer Drug Research·Phase 1·NCT03227016·30 enrolled
Safety and Efficacy1 trial
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Recruiting·—·Phase 1·NCT05101551·34 enrolled
Metastatic Colorectal Cancer1 trial
Glioblastoma1 trial
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Completed·—·Phase 2·NCT01004874·80 enrolled
Advanced Solid Malignancies1 trial
Celecoxib1 trial
Bevacizumab1 trial
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Completed·—·Phase 2·NCT00343044·40 enrolled
Impaired Renal Function1 trial
PARP Inhibitor1 trial
Progressive Multifocal Leukoencephalopathy1 trial
Glioblastoma Multiforme1 trial
Unspecified4 trials
Show 1 more trial
Cabozantinib With Topotecan-Cyclophosphamide
Completed·—·Phase 1·NCT04661852·12 enrolled
Regulatory
FDA Approval Timeline[5]
May 28, 1996
HYCAMTIN
NDA NDA020671
Oct 11, 2007
HYCAMTIN
NDA NDA020981
Feb 2, 2011
TOPOTECAN HYDROCHLORIDE
NDA NDA200582
Feb 25, 2011
TOPOTECAN
NDA NDA200199
Dec 20, 2012
TOPOTECAN HYDROCHLORIDE
NDA NDA022453
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Hycamtin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Topotecan. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]